Docetaxel plus ramucirumab (DR) versus docetaxel plus placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.

被引：0

作者：

Hosomi, Yukio

Yoh, Kiyotaka

Kasahara, Kazuo

Yamada, Kazuhiko

Takahashi, Toshiaki

Tanaka, Kaoru

Hida, Toyoaki

Yoshioka, Hiroshige

Kato, Terufumi

Takeda, Koji

Nishio, Makoto

Sakai, Hiroshi

Maemondo, Makoto

Takenoyama, Mitsuhiro

Nokihara, Hiroshi

Tatsumi, Masumi

Nakamura, Takashi

Enatsu, Sotaro

Tamura, Tomohide

Nakagawa, Kazuhiko

机构：

[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan

[3] Kanazawa Univ, Grad Sch Med Sci, Dept Resp Med, Cellular Transplantat Biol, Kanazawa, Ishikawa, Japan

[4] Kurume Univ, Sch Med, Kurume, Fukuoka 830, Japan

[5] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan

[6] Kiniki Univ, Fac Med, Osaka, Japan

[7] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan

[8] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan

[9] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan

[10] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan

[11] Japanese Fdn Canc Res, Tokyo, Japan

[12] Saitama Canc Ctr, Saitama, Japan

[13] Miyagi Canc Ctr, Sendai, Miyagi, Japan

[14] Kyushu Canc Ctr, Natl Hosp Org, Fukuoka, Japan

[15] Natl Canc Ctr, Tokyo, Japan

[16] Eli Lilly Japan, Kobe, Hyogo, Japan

[17] Lilly Res Labs Japan, Kobe, Hyogo, Japan

[18] St Lukes Int Hosp, Tokyo, Japan

[19] Kinki Univ, Fac Med, Osakasayama, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8054

引用

页数：1

共 50 条

[1] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
Herbst, R. S.
Sun, Y.
Korfee, S.
Germonpre, P.
Saijo, N.
Zhou, C.
Wang, J.
Langmuir, P.
Kennedy, S. J.
Johnson, B. E.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[2] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
Herbst, R. S.
Sun, Y.
Korfee, S.
Germonpre, P.
Saijo, N.
Zhou, C.
Wang, J.
Langmuir, P.
Kennedy, S. J.
Johnson, B. E.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
[3] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
Eberhardt, W. E. E.
Johnson, B. E.
Sun, Y.
Germonpre, P.
Saijo, N.
Zhou, C.
Wang, J.
Tada, H.
Kennedy, S.
Herbst, R. S.
EJC SUPPLEMENTS, 2009, 7 (02): : 505 - 505
[4] Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Egbert F. Smit
Edward B. Garon
Martin Reck
Federico Cappuzzo
Paolo Bidoli
Roger B. Cohen
Ling Gao
Lisa M. O’Brien
Pablo Lee
Annamaria Zimmermann
David R. Ferry
Allen S. Melemed
Maurice Pérol
Cancer Chemotherapy and Pharmacology, 2018, 82 : 77 - 86
[5] Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).
Janne, Pasi A.
Shaw, Alice Tsang
Pereira, Jose Rodrigues
Jeannin, Gaelle
Vansteenkiste, Johan
Barrios, Carlos H.
Franke, Fabio A.
Grinsted, Lynda
Smith, Paul D.
Zazulina, Victoria
Smith, Ian C.
Crino, Lucio
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Smit, Egbert F.
Garon, Edward B.
Reck, Martin
Cappuzzo, Federico
Bidoli, Paolo
Cohen, Roger B.
Gao, Ling
O'Brien, Lisa M.
Lee, Pablo
Zimmermann, Annamaria
Ferry, David R.
Melemed, Allen S.
Perol, Maurice
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 77 - 86
[7] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC)
Herbst, Roy S.
Sun, Yan
Korfee, Soenke
Germonpre, Paul
Saijo, Nagahiro
Zhou, Caichun
Wang, Jie
Langmuir, Peter
Tada, Hiroomi
Kennedy, Sarah J.
Johnson, Bruce E.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S357 - S358
[8] Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial.
Pectasides, D
Farmakis, D
Pectasides, M
Kostopoulou, V
Nikolaou, M
Koumpou, M
Gaglia, A
Kountourakis, P
Mylonakis, N
Economopoulos, T
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
[9] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
Herbst, Roy S.
Sun, Yon
Eberhardt, Wilfried E. E.
Germonpre, Paul
Saijo, Nagahiro
Zhou, Caicun
Wang, Jie
Li, Longyun
Kabbinavar, Fairooz
Ichinose, Yukito
Qin, Shukui
Zhang, Li
Biesma, Bonne
Heymach, John V.
Langmuir, Peter
Kennedy, Sarah J.
Tada, Hiroomi
Johnson, Bruce E.
LANCET ONCOLOGY, 2010, 11 (07): : 619 - 626
[10] Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
Georgoulias, V
Papadakis, E
Alexopoulos, A
Stavrinidis, E
Bania, E
Rapti, A
Grigoratou, T
Kouroussis, C
Kakolyris, S
Samonis, G
EUROPEAN JOURNAL OF CANCER, 1999, 35 : S249 - S249

← 1 2 3 4 5 →